Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C12H12N2O4 |
| Molecular Weight | 248.2347 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=CN([C@@H]2O[C@](CO)(C=C2)C#C)C(=O)NC1=O
InChI
InChIKey=OSYWBJSVKUFFSU-SKDRFNHKSA-N
InChI=1S/C12H12N2O4/c1-3-12(7-15)5-4-9(18-12)14-6-8(2)10(16)13-11(14)17/h1,4-6,9,15H,7H2,2H3,(H,13,16,17)/t9-,12+/m1/s1
| Molecular Formula | C12H12N2O4 |
| Molecular Weight | 248.2347 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Censavudine (also known as BMS-986001) is thymidine analogue and nucleosidereverse transcriptase inhibitors developed by Bristol Myers-Squibb for the treatment of HIV infection. In single-cycle assays, Censavudine inhibited HIV-2 isolates from treatment-naive individuals, with 50% effective concentrations (EC50s) ranging from 30 to 81 nM. Censavudine is the first nucleoside analog that, when tested against a diverse collection of HIV-1 and HIV-2 isolates, exhibits more potent activity against HIV-2 than against HIV-1 in culture. In clinical trials Censavudine was generally well tolerated through week 48 and similar efficacy to that of tenofovir disoproxil fumarate
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| In vitro cross-resistance profile of nucleoside reverse transcriptase inhibitor (NRTI) BMS-986001 against known NRTI resistance mutations. | 2013-11 |
|
| Impact of novel human immunodeficiency virus type 1 reverse transcriptase mutations P119S and T165A on 4'-ethynylthymidine analog resistance profile. | 2009-11 |
|
| Comparative study of the persistence of anti-HIV activity of deoxynucleoside HIV reverse transcriptase inhibitors after removal from culture. | 2009-04-22 |
|
| Highly selective action of triphosphate metabolite of 4'-ethynyl D4T: a novel anti-HIV compound against HIV-1 RT. | 2007-03 |
|
| Synthesis and anti-human immunodeficiency virus activity of 4'-branched (+/-)-4'-thiostavudines. | 2006-12-28 |
|
| Nucleophilic substitution at the 4'-position of nucleosides: new access to a promising anti-HIV agent 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine. | 2006-06-09 |
|
| Anti-human immunodeficiency virus type 1 activity and resistance profile of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine in vitro. | 2005-08 |
|
| A new approach to the synthesis of 4'-carbon-substituted nucleosides: development of a highly active anti-HIV agent 2', 3'-didehydro-3'-deoxy-4'-ethynylthymidine. | 2005 |
|
| Novel 4'-substituted stavudine analog with improved anti-human immunodeficiency virus activity and decreased cytotoxicity. | 2004-05 |
|
| An alternative method suitable for a large scale synthesis of 4'-ethynyl-2',3'-didehydro-3'-deoxythymidine. | 2004 |
|
| Synthesis and anti-HIV activity of 4'-cyano-2',3'-didehydro-3'-deoxythymidine. | 2004 |
|
| Synthesis of a highly active new anti-HIV agent 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine. | 2003-11-03 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 20:06:13 GMT 2025
by
admin
on
Mon Mar 31 20:06:13 GMT 2025
|
| Record UNII |
6IE83O6NGA
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
FESTINAVIR
Created by
admin on Mon Mar 31 20:06:13 GMT 2025 , Edited by admin on Mon Mar 31 20:06:13 GMT 2025
|
PRIMARY | |||
|
C166942
Created by
admin on Mon Mar 31 20:06:13 GMT 2025 , Edited by admin on Mon Mar 31 20:06:13 GMT 2025
|
PRIMARY | |||
|
DB12074
Created by
admin on Mon Mar 31 20:06:13 GMT 2025 , Edited by admin on Mon Mar 31 20:06:13 GMT 2025
|
PRIMARY | |||
|
DTXSID50212893
Created by
admin on Mon Mar 31 20:06:13 GMT 2025 , Edited by admin on Mon Mar 31 20:06:13 GMT 2025
|
PRIMARY | |||
|
9863
Created by
admin on Mon Mar 31 20:06:13 GMT 2025 , Edited by admin on Mon Mar 31 20:06:13 GMT 2025
|
PRIMARY | |||
|
CHEMBL124363
Created by
admin on Mon Mar 31 20:06:13 GMT 2025 , Edited by admin on Mon Mar 31 20:06:13 GMT 2025
|
PRIMARY | |||
|
ZZ-75
Created by
admin on Mon Mar 31 20:06:13 GMT 2025 , Edited by admin on Mon Mar 31 20:06:13 GMT 2025
|
PRIMARY | |||
|
1097733-37-3
Created by
admin on Mon Mar 31 20:06:13 GMT 2025 , Edited by admin on Mon Mar 31 20:06:13 GMT 2025
|
ALTERNATIVE | |||
|
3008897
Created by
admin on Mon Mar 31 20:06:13 GMT 2025 , Edited by admin on Mon Mar 31 20:06:13 GMT 2025
|
PRIMARY | |||
|
SUB33640
Created by
admin on Mon Mar 31 20:06:13 GMT 2025 , Edited by admin on Mon Mar 31 20:06:13 GMT 2025
|
PRIMARY | |||
|
634907-30-5
Created by
admin on Mon Mar 31 20:06:13 GMT 2025 , Edited by admin on Mon Mar 31 20:06:13 GMT 2025
|
PRIMARY | |||
|
100000127595
Created by
admin on Mon Mar 31 20:06:13 GMT 2025 , Edited by admin on Mon Mar 31 20:06:13 GMT 2025
|
PRIMARY | |||
|
6IE83O6NGA
Created by
admin on Mon Mar 31 20:06:13 GMT 2025 , Edited by admin on Mon Mar 31 20:06:13 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
TARGET ORGANISM->INHIBITOR |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
